Voya Financial Advisors Inc. cut its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,088 shares of the medical instruments supplier’s stock after selling 143 shares during the quarter. Voya Financial Advisors Inc.’s holdings in Becton, Dickinson and were worth $1,009,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of BDX. Flagship Private Wealth LLC purchased a new stake in Becton, Dickinson and in the fourth quarter valued at approximately $25,000. Dimension Capital Management LLC purchased a new stake in Becton, Dickinson and in the third quarter valued at approximately $29,000. Kempen Capital Management N.V. purchased a new stake in Becton, Dickinson and in the fourth quarter valued at approximately $29,000. Sage Private Wealth Group LLC acquired a new position in Becton, Dickinson and during the fourth quarter valued at approximately $37,000. Finally, Fort Pitt Capital Group LLC acquired a new position in Becton, Dickinson and during the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 83.22% of the company’s stock.
BDX has been the topic of a number of recent research reports. Raymond James lifted their price target on shares of Becton, Dickinson and from $270.00 to $282.00 and gave the company an “outperform” rating in a research report on Friday, January 29th. TheStreet raised shares of Becton, Dickinson and from a “c+” rating to an “a-” rating in a research report on Thursday, February 4th. Piper Sandler lifted their price target on shares of Becton, Dickinson and from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 4th. Wells Fargo & Company cut shares of Becton, Dickinson and from an “overweight” rating to an “equal weight” rating and set a $265.00 price target on the stock. in a research report on Tuesday, December 15th. Finally, Morgan Stanley upgraded shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $262.00 to $297.00 in a research note on Tuesday, December 15th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $281.08.
Becton, Dickinson and (NYSE:BDX) last released its earnings results on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share for the quarter, beating the consensus estimate of $3.14 by $1.41. Becton, Dickinson and had a net margin of 5.11% and a return on equity of 13.30%. The firm had revenue of $5.32 billion during the quarter, compared to analyst estimates of $4.87 billion. During the same quarter in the previous year, the firm earned $2.65 earnings per share. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. As a group, analysts expect that Becton, Dickinson and Company will post 12.5 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Wednesday, March 31st. Stockholders of record on Wednesday, March 10th were given a dividend of $0.83 per share. The ex-dividend date was Tuesday, March 9th. This represents a $3.32 annualized dividend and a dividend yield of 1.36%. Becton, Dickinson and’s dividend payout ratio is currently 32.55%.
Becton, Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: What are trading strategies for the 52-week high/low?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.